Aptevo Therapeutics may sell up to $2.31M in stock

The current limit follows a one-third-of-Public-Float cap in any 12-month period while Public Float remains below $75,000,000.

Rhea-AI Filing Summary

Aptevo Therapeutics Inc. (APVO) may offer and sell additional common stock with an aggregate offering price of up to $2,309,834 from time to time through Roth Capital Partners as sales agent under its at-the-market agreement. The amount is subject to Form S-3’s limit of one-third of Public Float in any 12-month period while Public Float remains below $75,000,000.

Public Float as of October 30, 2026 was $6,929,502, based on 2,665,193 shares of common stock issued and outstanding and held by non-affiliates on that date, and a share price of $2.60 as of September 2, 2026. Aptevo reported 303,157 shares sold under the Sales Agreement and Prior Prospectus for aggregate gross sale proceeds of $11,799,276. It also reported $0 of securities sold under General Instruction I.B.6 during the prior 12-month period. If Public Float increases enough to permit a greater amount of sales, Aptevo says it will file another prospectus supplement before making those sales.

Key Figures

Additional aggregate offering price: Up to $2,309,834 Public Float: $6,929,502 Non-affiliate shares issued and outstanding: 2,665,193 shares +5 more

8 metrics

Additional aggregate offering price Up to $2,309,834 Shares Aptevo may currently offer and sell through Roth Capital Partners as sales agent

Public Float $6,929,502 As of October 30, 2026

Non-affiliate shares issued and outstanding 2,665,193 shares As of October 30, 2026

Public Float share price $2.60 per share As of September 2, 2026

Shares sold under Sales Agreement and Prior Prospectus 303,157 shares As of October 30, 2026

Aggregate gross sale proceeds $11,799,276 From shares sold under the Sales Agreement and Prior Prospectus

Securities sold under General Instruction I.B.6 $0 During the prior 12-month period ending October 30, 2026

Last reported sale price $1.34 per share October 30, 2026

Key Terms

At The Market Offering Agreement, Public Float, General Instruction I.B.6, aggregate offering price

4 terms

At The Market Offering Agreement financial

"pursuant to that certain At The Market Offering Agreement"

An at-the-market offering agreement is a contract that lets a company sell newly issued shares directly into the open market through a broker, at whatever price the stock is trading at that moment. For investors this matters because it can increase the number of shares available (which may dilute existing ownership) while providing a flexible, often faster way for the company to raise cash without fixing a price, similar to a vendor selling small batches at current market stalls rather than setting a single fixed price.

Public Float financial

"the aggregate market value of issued and outstanding shares"

Public float is the total number of a company's shares that are available for trading by the general public. It excludes shares held by company insiders or large stakeholders who are unlikely to sell them easily. This figure helps investors understand how much of the company's stock is actively available, which can influence its liquidity and how easily its price might change.

General Instruction I.B.6 regulatory

"Pursuant to General Instruction I.B.6 of Form S-3"

aggregate offering price financial

"having an aggregate offering price of up to $50,000,000"

The aggregate offering price is the total dollar amount that will be raised if all the securities in an offering are sold at the stated offering price, before fees or expenses are taken out. Investors use it to gauge the size of the fundraising and its potential effects—such as how much cash the company will get and how much existing ownership might be reduced—similar to totaling every item’s price in a shopping cart to see the full bill.

Offering Details

ATM · Up to $2,309,834 aggregate offering price

Offering

Offering Type ATM

Securities Offered Common stock, $0.001 par value per share

Offering Amount Up to $2,309,834 aggregate offering price

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much common stock can APVO currently sell through its ATM?

Aptevo may currently offer and sell additional common shares with an aggregate offering price of up to $2,309,834 through Roth Capital Partners as sales agent. The sales are subject to the Form S-3 limit of one-third of Public Float in any 12-month period while Public Float remains below $75,000,000.

How much has APVO sold under its ATM agreement?

As of October 30, 2026, Aptevo reported 303,157 shares sold under the Sales Agreement and Prior Prospectus for aggregate gross sale proceeds of $11,799,276. It separately reported $0 of securities sold under General Instruction I.B.6 during the prior 12-month period.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/30/2026 - 04:36 PM EDT Accepted by SEC EDGAR 10/30/2026 - 04:36 PM EDT Learn about SEC filing dates

PROSPECTUS SUPPLEMENT (To Prospectus dated February 26, 2025) Filed Pursuant to Rule 424(b)(5) Registration No. 333-284969

Up to $2,309,834

This prospectus supplement amends and supplements the information in the prospectus, dated February 26, 2025, filed with the Securities and Exchange Commission as a part of our registration statement on Form S-3 (File No. 333-284969) (the “Registration Statement”), as previously supplemented by our prospectus supplements, dated April 28, 2025 (the “April 28, 2025 Prospectus Supplement” and together with the Registration Statement, the “Original Prospectus”), April 29, 2025 (collectively with the Original Prospectus, the “April 29, 2025 Prospectus”), May 22, 2025 (collectively with the April 29, 2025 Prospectus, the “May 22, 2025 Prospectus”) and June 20, 2025 (collectively with the May 22, 2025 Prospectus, the “Prior Prospectus”), relating to the offer and sale of a number of shares of our common stock, $0.001 par value per share, having an aggregate offering price of up to $50,000,000 (“Shares”), pursuant to that certain At The Market Offering Agreement we previously entered into with Roth Capital Partners ("Roth") on April 28, 2025 (the “Sales Agreement”). This prospectus supplement should be read in conjunction with the Prior Prospectus, and is qualified by reference thereto, except to the extent that the information herein amends or supersedes the information contained in the Prior Prospectus. This prospectus supplement is not complete without and may only be delivered or utilized in connection with, the Prior Prospectus and any future amendments or supplements thereto.

As of the date of this prospectus supplement, we have sold 303,157 shares of our common stock at an aggregate gross offering price of $38.92 pursuant to the Sales Agreement and the Prior Prospectus for aggregate gross sale proceeds of $11,799,276. We are filing this prospectus supplement to amend the Prior Prospectus to revise the amount we may offer and sell under the registration statement of which this prospectus supplement and the Prior Prospectus form a part following an increase in the aggregate market value of issued and outstanding shares of our common stock held by non-affiliates (our “Public Float”).

Pursuant to General Instruction I.B.6 of Form S-3, in no event may we sell, pursuant to the registration statement of which this prospectus supplement and the Prior Prospectus form a part, securities in a public primary offering with a value exceeding one-third of our Public Float in any 12-month period, so long as our Public Float remains below $75,000,000. Our Public Float as of October 30, 2026 was $6,929,502 based on 2,665,193 shares of our common stock issued and outstanding and held by non-affiliates on October 30, 2026, and a price per share of $2.60 as of September 2, 2026, which is a date within 60 days prior to the filing date of this prospectus supplement. As of the date hereof, we have sold securities with an aggregate market value of $0 pursuant to General Instruction I.B.6 of Form S-3 during the prior 12-month period that ends on and includes the date hereof.

As a result of the limitations of General Instruction I.B.6 of Form S-3, and in accordance with the terms of the Sales Agreement, we may currently offer and sell additional shares of our common stock having an aggregate offering price of up to $2,309,834 from time to time through Roth as sales agent. If our Public Float increases such that we may sell a greater amount of shares of our common stock under the Sales Agreement and the registration statement of which this prospectus supplement and the Prior Prospectus form a part, we will file another prospectus supplement prior to making such sales.

Our common stock is listed on The Nasdaq Capital Market under the symbol “APVO.” The last reported sale price of our common stock on October 30, 2026, was $1.34 per share.

Investing in our securities involves risks. See “Risk Factors” on page S-7 of the Original Prospectus, and in the filings with the Securities and Exchange Commission that are incorporated by reference into the Prior Prospectus and this prospectus supplement, for certain risks you should consider. You should read all the information set forth in this prospectus supplement and the Prior Prospectus, as well as the documents incorporated by reference herein and the Prior Prospectus, carefully before you make your investment decision.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if the Prior Prospectus, this prospectus supplement or the accompanying prospectus are truthful or complete. Any representation to the contrary is a criminal offense.

Roth Capital Partners

The date of this prospectus supplement is October 30, 2026